Erik Roy Hillesland v. Glenmark Pharmaceuticals, Inc. USA

• Court: Court of Appeals for the Eleventh Circuit
• Decided: November 9, 2023
• Docket: 23-11047
• Status: Unpublished

Opinion

USCA11 Case: 23-11047 Document: 28-1 Date Filed: 11/09/2023 Page: 1 of 2

[DO NOT PUBLISH] In the United States Court of Appeals For the Eleventh Circuit

____________________

No. 23-11047 Non-Argument Calendar ____________________

IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION. 9:20-md-02924-RLR ___________________________________________________ ERIK ROY HILLESLAND, CHANMEIKA HILL, Interested Parties-Appellants, versus GLENMARK PHARMACEUTICALS, INC. USA, MARLENE GOLDENBERG, APOTEX CORP., MICHAEL MCCANDLESS, USCA11 Case: 23-11047 Document: 28-1 Date Filed: 11/09/2023 Page: 2 of 2

2 Opinion of the Court 23-11047

BRAD ALDRIDGE, et al.,

Defendants-Appellees.

Appeal from the United States District Court for the Southern District of Florida D.C. Docket No. 9:20-md-02924-RLR ____________________

Before WILSON, JILL PRYOR, and GRANT, Circuit Judges. PER CURIAM: Upon review of the record and the response to the jurisdic- tional questions, this appeal is DISMISSED for lack of jurisdiction. Appellant lacks standing to bring this appeal because there is no evidence that he is, or ever was, a plaintiff in this action, and there is no indication that the district court has ever entered an appeala- ble order that caused him injury. See Wolff v. Cash 4 Titles, 351 F.3d 1348, 1353-54 (11th Cir. 2003); Mickles on behalf of herself v. Country Club, Inc., 887 F.3d 1270, 1278 (11th Cir. 2018).